Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06441617 · ClinicalTrials.gov registry record · NA

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

A NA study of Multiple Sclerosis and Fatigue, sponsored by Accelerated Cure Project for Multiple Sclerosis.

Recruiting
Registry status
NA
Development phase
2,000
Enrollment target
6
Study locations

NCT06441617: Recruiting NA study of Multiple Sclerosis and Fatigue, sponsored by Accelerated Cure Project for Multiple Sclerosis.

NCT06441617 is a NA study of Multiple Sclerosis and Fatigue that is actively recruiting participants, run by Accelerated Cure Project for Multiple Sclerosis. The registered enrollment target is 2,000 participants, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06441617, a NA study of Multiple Sclerosis and Fatigue, is actively recruiting participants, sponsored by Accelerated Cure Project for Multiple Sclerosis.

RECRUITING
Registry status
NA
Development phase
2,000 participants
Enrollment target
6
Study locations

Study Summary

CAFE-MS will assess the effectiveness of two online programs for fatigue in multiple sclerosis (MS). Although they differ, both of these online programs contain information about MS and fatigue intended to help people with MS understand and manage their fatigue. This large-scale, decentralized clinical trial is projected to enroll 2,000 people with MS. The collaboration between iConquerMS and 5 Veterans Affairs (VA) sites in the MS Centers of Excellence is designed to ensure sufficient representation of people with MS from populations traditionally under-represented in MS clinical trials. The study is a 3-arm, randomized controlled clinical trial with study participation lasting 1 year. Two of the trial arms will include one of two online programs for managing fatigue in MS added to the trial participants' usual MS treatment, and the third arm will include usual MS treatment alone. The online program phase of the trial lasts for 6 months after randomization followed by a final study visit at 12 months. Participants in the usual MS treatment alone arm for the first 6 months will have an opportunity to choose one of the online programs for the final 6 months of the trial.

Interventions

  • DEVICE Online Program for Fatigue

Study Locations (6)

District of Columbia

  • Washington VA Medical Center - Washington D.C.

Maryland

  • Baltimore VA Medical Center - Baltimore

Massachusetts

  • iConquerMS - Waltham

Oregon

  • Portland VA Medical Center - Portland

Tennessee

  • Nashville VA Medical Center - Nashville

Washington

  • Seattle VA Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2024-12-05
Est. Completion 2027-09-14
Phase NA

What NCT06441617 shows while recruiting

NCT06441617 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher).

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Online Program for Fatigue is the first listed.

NCT06441617 lists 6 locations in 6 states (District of Columbia, Maryland, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06441617 about?

NCT06441617 is a clinical study titled "Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis". CAFE-MS will assess the effectiveness of two online programs for fatigue in multiple sclerosis (MS). Although they differ, both of these online programs contain information about MS and fatigue intended to help people with MS understand and manage their fatigue. This large-scale, decentralized clin...

What is the current status of trial NCT06441617?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2024-12-05. Estimated completion is 2027-09-14.

What conditions does trial NCT06441617 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Fatigue.

What interventions are being tested in trial NCT06441617?

The interventions under investigation include: Online Program for Fatigue (DEVICE).

Who is sponsoring clinical trial NCT06441617?

This trial is sponsored by Accelerated Cure Project for Multiple Sclerosis, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06441617 being conducted?

This trial has 6 study locations across District of Columbia, Maryland, Massachusetts, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06441617's enrollment target sits among peer trials

2,000 15th of 315 higher than 299 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06441617, the US trial registry maintained by the National Library of Medicine. NCT06441617 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.